Leishmaniasis in humans: drug or vaccine therapy?

M Ghorbani, R Farhoudi - Drug design, development and therapy, 2017 - Taylor & Francis
Leishmania is an obligate intracellular pathogen that invades phagocytic host cells.
Approximately 30 different species of Phlebotomine sand flies can transmit this parasite …

Possibilities and challenges for develo** a successful vaccine for leishmaniasis

S Srivastava, P Shankar, J Mishra, S Singh - Parasites & vectors, 2016 - Springer
Leishmaniasis is a vector-borne disease caused by different species of protozoan parasites
of the genus Leishmania. It is a major health problem yet neglected tropical diseases, with …

A third generation vaccine for human visceral leishmaniasis and post kala azar dermal leishmaniasis: First-in-human trial of ChAd63-KH

M Osman, A Mistry, A Keding, R Gabe… - PLoS neglected …, 2017 - journals.plos.org
Background Visceral leishmaniasis (VL or kala azar) is the most serious form of human
leishmaniasis, responsible for over 20,000 deaths annually, and post kala azar dermal …

Chemotherapeutics of visceral leishmaniasis: present and future developments

S Sundar, A Singh - Parasitology, 2018 - cambridge.org
Treatment of Visceral Leishmaniasis (VL), a neglected tropical disease, is very challenging
with few treatment options. Long duration of treatment and drug toxicity further limit the target …

From infection to vaccination: reviewing the global burden, history of vaccine development, and recurring challenges in global leishmaniasis protection

G Volpedo, RH Huston, EA Holcomb… - Expert review of …, 2021 - Taylor & Francis
Introduction Leishmaniasis is a major public health problem and the second most lethal
parasitic disease in the world due to the lack of effective treatments and vaccines. Even …

Recent developments and future prospects in the treatment of visceral leishmaniasis

S Sundar, A Singh - Therapeutic advances in infectious …, 2016 - journals.sagepub.com
Limited therapeutic options in visceral leishmaniasis (VL) make the treatment of this
neglected disease very challenging. In addition to this, long treatment duration and toxic …

Cutaneous leishmaniasis situation analysis in the Islamic Republic of Iran in preparation for an elimination plan

I Sharifi, A Khosravi, MR Aflatoonian… - Frontiers in Public …, 2023 - frontiersin.org
Iran has invariably been under the growing public health threat of cutaneous leishmaniasis
(CL), a significant barrier to local development that hinders the prevention and control efforts …

Host–pathogen interaction in leishmaniasis: immune response and vaccination strategies

H Yasmin, A Adhikary, MN Al-Ahdal, S Roy, U Kishore - Immuno, 2022 - mdpi.com
Leishmaniasis is a zoonotic and vector-borne infectious disease that is caused by the genus
Leishmania belonging to the trypanosomatid family. The protozoan parasite has a digenetic …

Leishmaniasis: prevention, parasite detection and treatment

T Kobets, I Grekov, M Lipoldova - Current Medicinal Chemistry, 2012 - benthamdirect.com
Leishmaniasis remains a public health problem worldwide, affecting approximately 12
million people in 88 countries; 50 000 die of it each year. The disease is caused by …

The development and clinical evaluation of second-generation leishmaniasis vaccines

MS Duthie, VS Raman, FM Piazza, SG Reed - Vaccine, 2012 - Elsevier
Infection with Leishmania parasites results in a range of clinical manifestations and
outcomes. Control of Leishmania parasite transmission is extremely difficult due to the large …